4.21 USD
+0.13 (+3.19%)
4.2369 USD
+0.03 (+0.64%)
Overall ACB gets a fundamental rating of 3 out of 10. We evaluated ACB against 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ACB have multiple concerns. ACB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ACB has reported negative net income.
ACB had a positive operating cash flow in the past year.
ACB had negative earnings in 4 of the past 5 years.
ACB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ACB has a Return On Assets of -7.78%. This is in the better half of the industry: ACB outperforms 70.31% of its industry peers.
ACB's Return On Equity of -11.07% is fine compared to the rest of the industry. ACB outperforms 71.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.78% | ||
| ROE | -11.07% | ||
| ROIC | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 1.69%, ACB is in line with its industry, outperforming 50.00% of the companies in the same industry.
In the last couple of years the Gross Margin of ACB has declined.
ACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
2. Health
2.1 Basic Checks
ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACB has more shares outstanding
ACB has less shares outstanding than it did 5 years ago.
ACB has a better debt/assets ratio than last year.
2.2 Solvency
ACB has an Altman-Z score of -10.54. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
ACB has a worse Altman-Z score (-10.54) than 70.83% of its industry peers.
ACB has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
ACB's Debt to Equity ratio of 0.07 is in line compared to the rest of the industry. ACB outperforms 52.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.54 |
ROIC/WACCN/A
WACC8.15%
2.3 Liquidity
ACB has a Current Ratio of 3.41. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
ACB has a Current ratio (3.41) which is comparable to the rest of the industry.
ACB has a Quick Ratio of 1.63. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
ACB has a Quick ratio of 1.63. This is comparable to the rest of the industry: ACB outperforms 40.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.41 | ||
| Quick Ratio | 1.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 99.67% over the past year.
The Revenue has grown by 23.87% in the past year. This is a very strong growth!
Measured over the past years, ACB shows a small growth in Revenue. The Revenue has been growing by 6.94% on average per year.
EPS 1Y (TTM)99.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%157.81%
Revenue 1Y (TTM)23.87%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%14.31%
3.2 Future
ACB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.58% yearly.
Based on estimates for the next years, ACB will show a small growth in Revenue. The Revenue will grow by 7.92% on average per year.
EPS Next Y-288.53%
EPS Next 2Y206.48%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue Next Year8.72%
Revenue Next 2Y7.21%
Revenue Next 3Y6.87%
Revenue Next 5Y7.92%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Forward Earnings ratio of 12.61, ACB is valued correctly.
Based on the Price/Forward Earnings ratio, ACB is valued cheaply inside the industry as 84.38% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ACB to the average of the S&P500 Index (34.46), we can say ACB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.61 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ACB's earnings are expected to grow with 81.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y206.48%
EPS Next 3Y81.3%
5. Dividend
5.1 Amount
ACB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.21
+0.13 (+3.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners15.09%
Inst Owner Change54.99%
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap236.81M
Revenue(TTM)367.13M
Net Income(TTM)-58.89M
Analysts73.33
Price Target5.77 (37.05%)
Short Float %12.24%
Short Ratio4.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.2%
Min EPS beat(2)-216.23%
Max EPS beat(2)169.83%
EPS beat(4)2
Avg EPS beat(4)1005.23%
Min EPS beat(4)-426.74%
Max EPS beat(4)4494.06%
EPS beat(8)3
Avg EPS beat(8)458.8%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.15%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)5.14%
Revenue beat(4)3
Avg Revenue beat(4)4.75%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)13.79%
Revenue beat(8)6
Avg Revenue beat(8)4.5%
Revenue beat(12)8
Avg Revenue beat(12)4.15%
Revenue beat(16)9
Avg Revenue beat(16)2.98%
PT rev (1m)-0.66%
PT rev (3m)-10.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-127.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.61 | ||
| P/S | 0.91 | ||
| P/FCF | N/A | ||
| P/OCF | 148.49 | ||
| P/B | 0.63 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.33
Fwd EY7.93%
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)0.03
OCFY0.67%
SpS4.64
BVpS6.72
TBVpS5.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.78% | ||
| ROE | -11.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.69% | ||
| FCFM | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 86.37% | ||
| Cap/Sales | 5.6% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.41 | ||
| Quick Ratio | 1.63 | ||
| Altman-Z | -10.54 |
F-Score5
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%157.81%
EPS Next Y-288.53%
EPS Next 2Y206.48%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue 1Y (TTM)23.87%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%14.31%
Revenue Next Year8.72%
Revenue Next 2Y7.21%
Revenue Next 3Y6.87%
Revenue Next 5Y7.92%
EBIT growth 1Y-6.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.45%
EBIT Next 3Y30.77%
EBIT Next 5Y25.8%
FCF growth 1Y87.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.77%
OCF growth 3YN/A
OCF growth 5YN/A
AURORA CANNABIS INC / ACB FAQ
Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?
ChartMill assigns a fundamental rating of 3 / 10 to ACB.
Can you provide the valuation status for AURORA CANNABIS INC?
ChartMill assigns a valuation rating of 3 / 10 to AURORA CANNABIS INC (ACB). This can be considered as Overvalued.
What is the profitability of ACB stock?
AURORA CANNABIS INC (ACB) has a profitability rating of 2 / 10.